Secor Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Secor Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-8,728	Closed	-$3.04M	–	625
2017 Q4	$3.28M	Buy	8,728 +5,416	+164%	+$2.19M	0.13%	128
2017 Q3	$1.48M	Buy	3,312 +639	+24%	+$304K	0.14%	223
2017 Q2	$1.31M	Sell	2,673 -5,738	-68%	-$2.51M	0.12%	243
2017 Q1	$3.26M	Sell	8,411 -250	-3%	-$92.7K	0.36%	84
2016 Q4	$3.18M	Buy	8,661 +8,497	+5,181%	+$3.23M	0.39%	70
2016 Q3	$66K	Sell	164 -4,199	-96%	-$1.68M	0.01%	490
2016 Q2	$1.52M	Buy	4,363 +823	+23%	+$317K	0.19%	164
2016 Q1	$1.28M	Buy	+3,540	New	+$1.46M	0.18%	123
2014 Q4	–	Sell	-740	Closed	-$267K	–	449
2014 Q3	$267K	Buy	+740	New	+$248K	0.15%	240

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Secor Capital Advisors's REGN Position: Q1 2018 in Review

Secor Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2018, closing a stake of 8,728 shares — an estimated $3.04M sold.

Secor Capital Advisors first reported a position in REGN in Q3 2014 and held it in 9 quarters. The position peaked at $3.28M in Q4 2017. 619 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

Secor Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Secor Capital Advisors sold 8,728 Regeneron Pharmaceuticals shares in Q1 2018, an estimated $3.04M.
Secor Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2014 and held it in 9 quarters.
Secor Capital Advisors's Regeneron Pharmaceuticals position peaked at $3.28M in Q4 2017.
619 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on Secor Capital Advisors's 13F filing for Q1 2018, filed 15 May 2018.